Trial Profile
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SGN CD123A (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Seagen
- 08 May 2018 Status changed from recruiting to discontinued.
- 19 Sep 2016 According to a Seattle Genetics media release, first patient has been enrolled in this trial.
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.